

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
<b>Operational Services and Governance</b>	To ensure required levels of transparency, efficiency and accountability in the execution of responsibilities as stewards of quality use of medicines in Australia through focused management of the Grant Agreement.	<ul style="list-style-type: none"> <li>To effectively administer and manage the grant agreement and ensure all performance indicators, targets, milestones and deliverables are tracked.</li> <li>Work towards Corporate structure and operational arrangements in line with recommendations from the Review of Quality use Medicines Program delivery by NPS MedicineWise (The Review).</li> <li>To support internal organisational culture change program by building financial, agreement / contract management and reporting capability, and consumer centricity and QUM collaborations.</li> </ul>	\$2,672,626	Australian Government Department of Health and Aged Cared
<b>QUM Health Technologies Topic Selection</b>	<p>To drive quality use of medicines and health technologies across the Australian healthcare landscape and improve health outcomes through the identification of QUM priority areas for stewardship and future programs and activities that:</p> <ul style="list-style-type: none"> <li>Address areas of unmet need</li> <li>Are evidence based</li> <li>Aim to reduce medication misuse and improve health literacy</li> <li>Have potential to contribute to health system efficiencies including the MBS and PBS</li> <li>Support a collaborative and collective impact approach</li> </ul>	<ul style="list-style-type: none"> <li>Understand the QUM and health technology priorities of The Commonwealth and other key stakeholders.</li> <li>Understand the existing services and programs in the QUM ecosystem and ensure activities are complementary as appropriate.</li> <li>Apply an evidence-based research approach combined with stakeholder engagement and expert knowledge to identify priority issues.</li> <li>Identify opportunities for programs to be developed, implemented and/or measured in partnership in order to maximise impact, avoid duplication, and provide value for money.</li> <li>Identify programs that recognise and address emerging challenges related to ageing populations and complexity of managing people with co-morbidities and multiple medications.</li> <li>Identify QUM priorities that require systems-based interventions.</li> <li>Identify opportunities to demonstrate impact through: <ul style="list-style-type: none"> <li>Savings to the PBS and MBS</li> <li>Improved health or economic outcomes</li> <li>Reduced medication or other health technology mis-use</li> <li>Improved consumer health literacy as relates QUM and health technologies</li> <li>Cross-sector QUM-related activities</li> </ul> </li> </ul>	\$385,072	Australian Government Department of Health and Aged Cared
<b>Clinical Intervention Advisory Group (CIAG)</b>	<p>The Clinical Intervention Advisory Group (CIAG) supports NPS MedicineWise to deliver against Grant Agreement objectives through the provision of strategic advice on potential and current Quality Use of Medicines (QUM) Grant programs, products and services in order to:</p> <ul style="list-style-type: none"> <li>Ensure that QUM programs address unmet needs as identified through engagement with the relevant stakeholders</li> <li>Improve medicine and medical test decisions by health professionals and/or consumers</li> <li>Ensure that NPS MedicineWise is able to deliver innovative approaches to program delivery.</li> </ul>	<ul style="list-style-type: none"> <li>Program and activity selection: including current quality use of medicines or medical tests issues of high unmet need, relevant settings and target audiences and opportunities (including partnerships)</li> <li>Program and intervention design and effectiveness to support behaviour change programs: drawing from implementation science, social marketing, behavioural economics, and human centred design</li> <li>Program scope: assisting with development of clear program objectives and key messages</li> <li>Evaluation: advice on appropriate evaluation methodologies and questions</li> <li>Opportunities for innovation that deliver on Grant initiatives, including, but not limited to, reach to specialists and support for PBS/MBS sustainability.</li> <li>To support exploration of different methods to engage stakeholders in creating opportunities for collective impact.</li> <li>External activities that may impact on QUM activities.</li> </ul>	\$62,464	Australian Government Department of Health and Aged Cared

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
<b>Remote Area Aboriginal Health Service (RAAHS)</b>	To ensure a safe and effective QUM approach to the provision of medicines to residents of remote Aboriginal and Torres Strait Islander communities under the RAAHS program.	<ul style="list-style-type: none"> <li>Development of high quality and relevant education that is provided to all health professionals who may order, stock and supply PBS medicines under the RAAHS program.</li> <li>Development of guidance that takes into account the State/Territory or other relevant workforce or medicines protocols.</li> <li>To maximise leverage of existing resources to ensure they provide value for money and avoid unnecessary duplication.</li> <li>Employ effective stakeholder engagement to ensure a whole of setting approach in order to maximise uptake and impact.</li> </ul>	\$64,309	Australian Government Department of Health and Aged Cared
<b>Anticholinergics / Safe Use of Medicines for Older People</b>	Delivery of a national program to promote the efficacious and safe use of medicines that contribute to the anticholinergic burden for people over 65 across primary care, residential aged care facilities (RACFs) and at transitions of care	<ul style="list-style-type: none"> <li>Provide independent, evidence-based, information and education to health professionals about how to manage anticholinergic burden</li> <li>Increase health professional knowledge of medicines with anticholinergic effects and how to individualise the approach to reducing the anticholinergic burden that is aligned to consumer goals</li> <li>Increase level of consumer health literacy related to quality use of medicines, including potential benefits and harms</li> <li>Reduce inappropriate use of medicines with anticholinergic effects (and medicine-related harms)</li> <li>Identify medication safety tools and systems which impact the safe use of medicines with anticholinergic effects (e.g. Home Medicine Reviews [HMRs], Residential Medication Management Reviews [RMMRs] and Health assessment for people aged 75 years and older).</li> </ul>	\$240,432	Australian Government Department of Health and Aged Cared
<b>Psychotropic Medicines and Younger People</b>	Delivery of a national program to improve the quality use of psychotropic medicines and non-medicine options for people aged 16–24 years who present in primary care with psychological distress, depression and/or anxiety disorders.	<ul style="list-style-type: none"> <li>To increase the health literacy of people aged 16–24 years related to psychotropic medicines and non-medicine management options for mental health.</li> <li>To increase health professional knowledge, confidence and practice in the use of psychotropic medicines and non-medicine management options for mental health for people aged 16–24 years.</li> <li>To increase health professional use of non-medicine management options first-line for depression and anxiety disorders in people aged 16–24 years.</li> <li>To reduce the prescribing of antidepressants first-line for people aged 16–24 years with mild-to-moderate depression and/or anxiety disorders.</li> <li>Improved sustainability of the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS).</li> </ul>	\$2,053,584	Australian Government Department of Health and Aged Cared
<b>Chronic Kidney Disease</b>	Delivery of a national program to improve the screening, management, and quality use of medicines for people at risk of, and those with, CKD.	<ul style="list-style-type: none"> <li>To implement a national, independent, evidence-based education and behaviour change initiative on quality use of medicines in people with CKD</li> <li>To improve consumer health literacy, including for people with CKD and their carers, regarding kidney health and disease and quality use of medicines</li> <li>To increase health professional knowledge and confidence in the early detection, diagnosis and management of CKD (primarily stages 1 to 3b)</li> <li>To optimise prescribing of medicines related to CKD</li> <li>To reduce prescribing of medicines that contribute to worsening kidney disease and adverse events in people with CKD</li> <li>Increase health professional knowledge and confidence to adjust prescribed medicines eliminated by the kidneys according to current kidney function (stage of CKD) and comorbidities.</li> <li>To increase GP practices that optimise the early detection and management of CKD to delay disease progression</li> <li>To increase health professional utilisation and effectiveness of targeted screening for CKD (i.e., kidney health check)</li> <li>To increase health professional prescribing (or adjustment) of medicines shown to protect the kidney/cardiovascular system to slow the progression of CKD and improve cardiovascular outcomes</li> </ul>	\$1,421,542	Australian Government Department of Health and Aged Cared

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
		<ul style="list-style-type: none"> <li>To improve health outcomes for people with CKD</li> <li>Reduced Albumin/creatinine ratio (ACR) (3 and 6 months)</li> <li>Reduced hospitalisations</li> <li>Reduced mortality</li> <li>Increased health-related quality of life (estimated glomerular filtration rate [eGFR] linked to stage of CKD and Quality of Life)</li> <li>Increased time to dialysis (from date of CKD diagnosis).</li> </ul>		
<b>Opioid Analgesic Competency Support program</b>	To support the quality use of opioids and reduce opioid-related harms through provision of educational resources and interventions to support prescribing and dispensing competencies for health professionals in relation to opioids.	<p>Objectives for the workplan are to:</p> <ul style="list-style-type: none"> <li>work with Australian Commission on Safety and Quality in Health Care (ACSQHC) to develop opioid analgesic education to support and reinforce prescribing and dispensing competencies for health professionals including those working in emergency departments, surgical units and at transitions of care. <ul style="list-style-type: none"> <li>develop case-based educational interventions focused on opioids prescribing and dispensing that target career-long engagement.</li> <li>educational resources to reflect the intent of the Commission's Clinical Care Standard which encourages clinicians to reflect on, modify and align their opioid-prescribing practices with the Clinical Care Standard.</li> <li>engage with, Australian hospitals through ACSQHC and health professional' peak bodies on the development of education and training that support the existing prescribing and dispensing competencies for application to opioid analgesics for acute pain management</li> <li>actively promote the uptake of the educational interventions by targeting health professionals in, secondary and tertiary care and where appropriate transition to primary care.</li> </ul> </li> </ul> <p>This workplan will support the achievement of the following outcomes:</p> <ul style="list-style-type: none"> <li>Provision of independent, evidence-based information and education to health professionals.</li> <li>Increased uptake and health professional knowledge of and adherence to prescribing and dispensing competencies.</li> </ul>	\$90,400	Australian Government Department of Health and Aged Cared
<b>Good Medicine Better Health program</b>	<p>To improve Aboriginal and Torres Strait Islander Health Workers and Practitioners' (including Remote Area Aboriginal Health Services (RAAHS) workers) knowledge, skills and access to resources in quality use of medicines (QUM)</p> <p>Provide education that builds the competency and confidence of Aboriginal and Torres Strait Islander Health Workers (AHW) and Practitioners (HP) in the quality use of medicines and medical tests.</p> <p>Enable access to best resources to improve medicines literacy of Aboriginal and Torres Strait Islander communities.</p>	<ul style="list-style-type: none"> <li>Increase awareness of QUM among Aboriginal and Torres Strait Islander communities through the education of Aboriginal and Torres Strait Islander Health Workers and Practitioners</li> <li>Work in partnership with Aboriginal and Torres Strait Islander organisations, including National Aboriginal Community Controlled Health Organisation (NACCHO) and National Association of Aboriginal and Torres Strait Islander Health Workers and Practitioners (NAATSIHWP) to ensure that the program meets the needs of the diversity of health providers serving Indigenous people.</li> <li>Provide a flexible program that allows for adaptation to local communities.</li> <li>Incentivise participation by alignment of QUM online education with continuing professional development (CPD) and training requirements of Aboriginal and Torres Strait Islander Health Workers and Practitioners</li> <li>Provide consumer resources for AHW use to support improved QUM health literacy with consumers.</li> <li>Build and strengthen partnerships with the wider health sector that create opportunities for AHWs to play a broader role in QUM.</li> <li>Work in partnership with key stakeholders to measure program impact.</li> </ul>	\$186,982	Australian Government Department of Health and Aged Cared
<b>National Prescribing Curriculum (NPC)</b>	This program aims to improve health literacy and medication confidence among undergraduate and early-career health professionals as relates to QUM principles through building improved health literacy and medication confidence amongst undergraduate and early career prescribers through the ongoing support of the National Prescribing Curriculum.	<ul style="list-style-type: none"> <li>Provide and maintain independent, interactive evidence-based education services on quality use of medicines to support undergraduate prescribers (National Prescribing Curriculum).</li> <li>Provide a learning experience that increases user health literacy (as relates to QUM) and confidence in prescribing and communication using:</li> </ul>	\$100,516	Australian Government Department of Health and Aged Cared

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
		<ul style="list-style-type: none"> <li>real life situations in hospital and general practice settings.</li> <li>complex, authentic tasks, for example completing prescriptions for medicines.</li> <li>feedback from experts, and for right and wrong answers.</li> <li>links to current evidence-based resources including QUM grant publications, Therapeutic Guidelines and Australian Medicines Handbook.</li> <li>Incorporation of Choosing Wisely recommendations and principles.</li> </ul> <ul style="list-style-type: none"> <li>Increased proportion of medical and pharmacy schools participating in the program through targeted promotion and marketing.</li> </ul>		
<b>QUM Primary Care Framework</b>	<p>Improve Quality Use of Medicines (QUM) in primary care through working in partnership with Primary Health Networks (PHNs)</p> <p>Increase impact of QUM Grant Agreement programs through provision of QUM resources that meet PHN needs.</p>	<ul style="list-style-type: none"> <li>Identify PHN priorities, activities and opportunities as relate to QUM in primary care</li> <li>Implement a pilot project that supports improvements in QUM in primary care and leverages QUM program resources</li> <li>Develop a framework to support PHNs to embed QUM in future core activities.</li> </ul>	\$32,354	Australian Government Department of Health and Aged Cared
<b>Outcomes Evaluation</b>	<p>The Grant Agreement requires that programs and activities are evaluated in order to demonstrate impacts and outcomes that support quality use of medicines and health technologies in Australia. This work plan supports activities that will demonstrate impact of programs on activities on:</p> <ul style="list-style-type: none"> <li>Misuse of medicines and other health technologies</li> <li>Health Literacy as relates to Quality Use of Medicines</li> <li>Health and economic outcomes</li> <li>Sustainability of the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule</li> </ul>	<ul style="list-style-type: none"> <li>Comprehensive evaluation of all multi-faceted, national and regional programs funded under the QUM grant in order to demonstrate improvements in Quality Use of Medicines and health technologies</li> <li>Enable assessment of QUM programs with respect to value for money</li> <li>Support the selection of Topics for future programs and activities that will deliver on required program outcomes through the provision of cost savings forecasts reports and other feasibility assessments as required</li> <li>Utilisation of relevant and multiple data sets to demonstrate program outcomes</li> <li>Development and measurement of indicators to support measurement of QUM stewardship activities</li> <li>Demonstrate collective impact of multi-disciplinary QUM programs delivered in partnership</li> <li>Use of robust evaluation methodologies that have been agreed with The Commonwealth</li> <li>Provision of evaluation reports (in line with the Grant Agreement)</li> </ul>	\$280,632	Australian Government Department of Health and Aged Cared
<b>Program and Intervention Innovation</b>	<p>To assess the effectiveness and value for money of existing interventions and program models,</p> <p>Develop contemporary, evidence-based understanding of best practice behaviour change in QUM,</p> <p>Utilise MedicineInsight to show the effectiveness of program interventions.</p>	<ul style="list-style-type: none"> <li>Review of existing intervention suite and program delivery model.</li> <li>Continually innovate retained interventions.</li> <li>Pilot additional innovative QUM grant interventions and program models.</li> <li>Evaluate piloted interventions to identify improvements that can maximise their engagement and potential for their utilisation across QUM grant programs and clinical areas.</li> <li>Dissemination of information across the health sector that supports the design of activities to support a QUM collective impact approach.</li> </ul>	\$103,320	Australian Government Department of Health and Aged Cared
<b>MedicineWise App</b>	<p>To support improved health literacy and reduced medicines misuse by providing consumers with useful medicines management tools and information that support self-medicine-management, adherence, and safe use.</p> <p>Actively promote the MedicineWise app in line with recommendation 23 of The Review of the Quality Use of Medicines Program's Delivery by the National Prescribing Service Limited (NPS MedicineWise) Report (The Review).</p>	<ul style="list-style-type: none"> <li>Deliver personalised medicines information in line with key Quality Use of Medicines (QUM) issues</li> <li>Increase consumer and health professional uptake through effective promotion and partnering</li> <li>Increase the level of tailored content and useful health and medicines information available through new content and content-sharing partnerships</li> <li>Increase app user retention by providing a valuable health and medicine platform that is valued by users.</li> </ul>	\$568,969	Australian Government Department of Health and Aged Cared
<b>Consumer Engagement</b>	Grant programs and activities are influenced by Australian consumers throughout from planning, design, and implementation,	<p>Implement an effective consumer engagement plan that will:</p> <ul style="list-style-type: none"> <li>Identify issues consumers face using medicines and design enhanced models of care which address those issues</li> </ul>	\$270,765	Australian Government Department of Health and Aged Cared



## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
	to evaluation, to improve the quality use of medicines, lower medicine misuse and build health literacy.	<ul style="list-style-type: none"> <li>Improve the quality and suitability of products and services to a diverse range of consumers' needs</li> <li>Generate new and innovative ideas for quality use of medicines campaigns and programs</li> <li>Produce health information that is understandable which promote better use of medicines in line with quality use of medicines principles.</li> </ul> <p>Consumer engagement will have four key components intended to maximise both impact and sustainability of approach.</p> <ol style="list-style-type: none"> <li><b>Seeking consumer evidence and insights</b> from consumers, consumer representatives, communities and consumer organisations.</li> <li><b>Incorporating insights</b> into programs, products and services (direct to consumer, through partners and via health professionals).</li> <li><b>Building stakeholder and organisational capacity</b> through training and support to effectively seek and integrate consumer insights as well as supporting sustainability through embedding expertise</li> <li><b>Monitoring and continuously improving</b> by actively seeking feedback from consumers, partners and health professionals and incorporating feedback, measuring the impact of our work on consumer behaviour and experience and assessing the effectiveness of our engagement strategies.</li> </ol>		
<b>RACGP CPD Accreditation</b>	To support improved prescriber behaviour and reduce inappropriate prescribing and use of health technologies by General Practitioners by ensuring that educational activities developed under the Grant Agreement meet registration requirements for continuing professional development.	<ul style="list-style-type: none"> <li>Incentivise GP participation in QUM Grant educational activities through appropriate accreditation with RACGP</li> <li>QUM Grant educational programs are available through the RACGP CPD program for General Practitioners</li> <li>NPS MedicineWise personnel are skilled in the requirements for meeting relevant CPD education standards of RACGP.</li> </ul>	\$21,055	Australian Government Department of Health and Aged Cared
<b>Choosing Wisely Australia</b>	To promote and support a national conversation about unnecessary tests, treatments and procedures.  Improve health literacy as it relates to unnecessary tests, treatments and procedures  Reduce unnecessary use of tests, treatments and procedures.	<ul style="list-style-type: none"> <li>Change clinician and consumer attitudes to the use of unnecessary tests, treatments and procedures</li> <li>Foster consumer awareness and engagement of key messages and principles</li> <li>Demonstrate positive change in clinical practice to reduce the unnecessary use of tests, treatments and procedures.</li> <li>Promote alignment within the QUM system, i.e. integration into training, guidelines and policy.</li> </ul>	\$243,691	Australian Government Department of Health and Aged Cared
<b>Digital and Direct Communications Platform</b>	To provide and support a reliable digital platform for consumers and health professionals that hosts products and services that support quality use of medicines and health technologies.	<ul style="list-style-type: none"> <li>Use data to distribute and send updates/alerts to NPS MedicineWise publication subscribers (eg Australian Prescriber)</li> <li>Maintain relationships with key stakeholders, including health professionals through digital and direct communications</li> <li>Provide a platform to register and engage in continuing professional development (CPD) activities</li> <li>Increase health professional participation in CPD education activities</li> <li>Ensure continual accessibility of QUM information is available across platforms</li> </ul> <p>NB: This work plan does not include content development or updates to QUM/health technology content hosted on the relevant websites. Content development and updates to website content are included in the Digital Content workplan and other relevant workplans (e.g. National Prescribing Curriculum).</p>	\$905,067	Australian Government Department of Health and Aged Cared
<b>Digital Content</b>	Ensure contemporary, high-quality and up-to-date information to support the principles of quality use of medicines (QUM)/health technologies among consumers, their carers and health professionals in the Australian context.  Support adult learning principles for reflective learning and behaviour change.	<ul style="list-style-type: none"> <li>Provide and maintain evidence-based QUM/health technologies information and education that is up-to-date for health professional and consumer audiences</li> <li>Maintain continuing professional development (CPD) accreditation for relevant activities as an incentive for participation</li> <li>Maintain timely up-to-date content in line with relevant Government priorities and policy changes</li> <li>Contribute to improving health literacy of Australians.</li> </ul>	\$266,364	Australian Government Department of Health and Aged Cared
<b>Council of Therapeutic</b>	To provide insight into key quality use of medicines issues in the acute care sector and at transitions of care.	<ul style="list-style-type: none"> <li>Provide, expert, consensus-based collaborative advice and advocacy for the purpose of maximising influence on medicines policy and practice to ensure a quality use of medicines approach is applied across local, state and national policy and practices.</li> </ul>	\$58,096	Australian Government Department of Health and Aged Cared

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
<b>Advisory Groups (CATAG)</b>	Reduce misuse of medicines as relates to high cost medicines use in acute care.  Influence medication safety as medicines enter the medicines management cycle.	<ul style="list-style-type: none"> <li>To increase equity of patient access to safe, cost-effective and affordable medicines nationally through the development of resources to guide decision-making processes at the local and jurisdictional levels.</li> </ul>		
<b>MedicineInsight Maintenance</b>	MedicineInsight continues to be a robust, valuable and trusted national primary care data set that supports provision of post market surveillance and utilisation of data.	<ul style="list-style-type: none"> <li>Maintenance of a minimum number of 500 participating general practices through proactive and regular engagement with participating practices</li> <li>Ensure stakeholder trust in MedicineInsight through maintenance and oversight of best practice data governance processes and ethics frameworks</li> <li>Increase awareness of MedicineInsight data and its application through publication of data quality and insights</li> <li>Ensure MedicineInsight remains viable, contemporary and compatible with new, emerging and changing technologies through ongoing maintenance and sector engagement</li> </ul>	\$1,585,966	Australian Government Department of Health and Aged Cared
<b>MedicineInsight Data Linkage</b>	To enhance the functionality of MedicineInsight to support post market surveillance activities and to support health outcome studies for evaluation of programs through data linkage to external data sets	<ul style="list-style-type: none"> <li>Deliver a preferred linkage capability that can be used across the whole dataset.</li> <li>Demonstrate the success of the preferred linkage capability to connect MedicineInsight with external data sets.</li> <li>Analysis of linked data sets that will enable improved post market utilisation, surveillance data and health outcome studies.</li> <li>This workplan proposes to extend the schedule to December 2022 to complete a second linkage project and continue exploring future linkage opportunities.</li> </ul>	\$74,417	Australian Government Department of Health and Aged Cared
<b>MedicineInsight Data Validation</b>	Ensure that MedicineInsight accurately reflects general practice data and to ensure production of high-quality post market surveillance reports.	<ul style="list-style-type: none"> <li>In consultation with The Commonwealth, identify current gaps in MedicineInsight general practice data,</li> <li>prioritise data validation activities in line with Commonwealth priorities</li> <li>publication of data validation reports in line with Commonwealth priorities.</li> </ul>	\$127,035	Australian Government Department of Health and Aged Cared
<b>MedicineInsight Data Visualisation</b>	To enhance MedicineInsight's offering to participating general practices and the Department of Health and associated stakeholders with the broad goal of supporting post market surveillance activities and improving patient outcomes.  To evolve and expand the usage of Power BI, a data visualisation tool, an investment delivered in Schedule 8A): Workplan MedicineInsight Maintenance in FY20-21.	<ul style="list-style-type: none"> <li>Deliver interactivity and ability to visualise MedicineInsight reports for key end user groups.</li> <li>Deliver additional value to the Department of Health and other stakeholders.</li> <li>Deliver additional value to participating general practices to support ongoing participation and recruitment.</li> </ul>	\$201,886	Australian Government Department of Health and Aged Cared
<b>MedicineInsight Privacy Impact Assessment and Consent Model Review</b>	Continue the implementation of outstanding recommendations from the MedicineInsight Consent Model Review (CMR) to: <ul style="list-style-type: none"> <li>Develop and publish a plain language version of the governance framework around the use of MedicineInsight data among consumers.</li> <li>Create greater transparency through revision of existing MedicineInsight web communications and introduction of resources for consumers to promote and support ongoing confidence and engagement in the program and projects.</li> <li>Implement findings from consumer partner workshops (convened as part of 2021/22 Privacy Impact assessment and Consent Model Review Workplan) through the development and distribution of culturally appropriate materials.</li> </ul>	<ul style="list-style-type: none"> <li>Complete implementation of the communications plan (CMR Recommendation 1).</li> <li>Revise existing material and website content to provide accessible and plain-language information about the program to consumers (CMR Recommendations 2 and 8).</li> <li>Explore mechanisms to strengthen direct consumer dialogue with MedicineInsight participants (CMR Recommendation 15).</li> <li>Support researchers to engage consumers in MedicineInsight projects through the promotion of tailored resources (CMR Recommendation 10).</li> <li>Create and maintain tailored culturally appropriate materials to ensure the cultural safety and data sovereignty of consumers is respected and scope processes required to undertake dedicated Indigenous research that proactively engage the Indigenous research sector and community in study design (CMR Recommendation 15).</li> </ul>	\$133,757	Australian Government Department of Health and Aged Cared

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
	<ul style="list-style-type: none"> <li>Understand how the use of MedicineInsight can be supported among the Indigenous research sector to strengthen dedicated Indigenous research.</li> <li>Enable new QUM activities that support Schedule 8a MedicineInsight Maintenance that are not currently funded under Schedule 8A*. These new activities will support the following:- <ul style="list-style-type: none"> <li>Schedule 8a MedicineInsight Maintenance Performance Indicator: <i>“Demonstrated improvement in Data Governance as outlined in the review Recommendation”</i> ensuring that <i>“there is transparency in the MedicineInsight data governance”</i>.</li> <li>2022-23 Workplan Objective 2, page 1: <i>“..ensure stakeholder trust in MedicineInsight through maintenance and oversight of best practice data governance processes and ethics frameworks...including those related to data collection and use”</i> which remaining CMR recommendations are focused toward.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Assist MedicineInsight general practice recruitment under Schedule 8a through the development of culturally appropriate materials for Indigenous community. The new culturally appropriate materials will assist NPS MedicineWise to recruit more Aboriginal Medical Services.</li> <li>Strengthen the transparency of data utility and data governance relating to currently funded grant activities proposed under Schedule 9a Post Market Surveillance by maintaining social license, data sovereignty and community expectations.</li> </ul>		
<b>MedicineInsight Post Market Surveillance</b>	Improved post-market surveillance through the provision of data insights that provide policymakers, regulators and other government agencies with timely and useful information on use of medications and health technologies in Australia, both at the national and local level.	<ul style="list-style-type: none"> <li>Provision of regular MedicineInsight reports with up-to-date information that address areas of interest as specified by the Commonwealth.</li> <li>Implementation of an agreed framework for engagement with the Department, TGA and other government agencies to support post-market surveillance, particularly with regards to surveillance and monitoring of safety and appropriate use of medicines.</li> <li>Development and delivery of a strategic plan that: <ul style="list-style-type: none"> <li>clearly articulates the place of MedicineInsight in supporting post-market surveillance activities</li> <li>identifies gaps, barriers and threats to the ability of MedicineInsight to support the needs of policy-makers and regulators; and</li> <li>identifies strategies and measures that can be taken to overcome these gaps, barriers and threats</li> </ul> </li> <li>Increased capability of MedicineInsight to support post-market surveillance activities for policy makers, regulators and other government agencies.</li> <li>Publication of approved MedicineInsight data insights in peer reviewed journals.</li> </ul>	\$254,637	Australian Government Department of Health and Aged Cared
<b>MedicineInsight Data Collection from Specialists</b>	To support improved post market surveillance through use of specialist prescribing insights	<ul style="list-style-type: none"> <li>Assess the feasibility of collecting specialist data from specialist clinical information systems (CIS) into MedicineInsight. This will include: <ul style="list-style-type: none"> <li>Engagement with, and identification of specialist practices suitable to participate in data collection</li> <li>Identification of any governance changes and dependencies required</li> <li>Ensuring specialist awareness of intent to collect data</li> </ul> </li> <li>Undertake a pilot program to assess the feasibility of using data from specialists (private practice)</li> <li>Provide a feasibility report on collected specialist data and its potential to inform quality use of medicines (QUM) activities.</li> </ul>	\$12,832	Australian Government Department of Health and Aged Cared
<b>Australian Prescriber</b>	To provide independent evidence-based information for health professionals on drugs, therapeutics and health technologies in the Australian context.	<ul style="list-style-type: none"> <li>Produce and disseminate regular and timely publications</li> <li>Provide publications that contain critical commentary on drugs and therapeutics for health professionals including post market use</li> <li>Leverage post market surveillance insights (where appropriate) to highlight issues relating to Quality Use of Medicines (QUM) and health technologies</li> </ul>	\$535,123	Australian Government Department of Health and Aged Cared

## QUALITY USE OF MEDICINES GRANT AGREEMENT WORKPLAN ACTIVITIES 1 JULY 2022 – 31 DECEMBER 2022

Activities / Programs	Program Goal	Program Objectives	Total Program Costs FY2022-2023 (6 month funding period 1 July - 31 December 2022)	Funding Source
		<ul style="list-style-type: none"> <li>Prioritise emerging issues and high QUM/health technology needs.</li> <li>Increase the number of subscribers to Australian Prescriber communications.</li> </ul>		
<b>Communication Policy</b>	To increase awareness of new and emerging issues relating to medicines and health technologies in order for health professionals and consumers to make evidence-based decisions about the medicines and other health technologies.	<ul style="list-style-type: none"> <li>Provide critical information on evidence relating to new or amended PBS, MBS and TGA listings</li> <li>Provide information that is clinically relevant and contextualised in order to best influence clinical practice</li> <li>Provide information that is timely, independent, evidence-based and developed using a robust clinical review process</li> <li>Deliver (as required) consumer information that is clear in language, accessible for all levels of ability, adheres to health literacy principles and supports person centred care</li> <li>Provide communications on policy changes that arise during the contract period and are identified by The Department as requiring additional and supporting content to be developed</li> <li>Promote publications to health professionals, stakeholders and consumers as appropriate.</li> <li>Work collaboratively with the Commonwealth in a review of RADAR to identify and determine an efficient and effective means of informing pharmacists and prescribers regarding PBS listings</li> </ul>	\$115,951	Australian Government Department of Health and Aged Cared
<b>QUM Transition</b>	<p>To contribute to the development of a plan for transitioning of nominated QUM programs and services to the ACSQHC or the Department.</p> <p>To deliver a draft Transition-Out Plan to the Commonwealth for review by 5 August 2022 and to finalise it following feedback (as required) in readiness for implementation.</p>	<ul style="list-style-type: none"> <li>To enable planning for the delivery on the requirements to transition NPS MedicineWise QUM services to the Australian Commission on Safety and Quality in Health Care (ACSQHC), as per the decision of Government at the March 2022 Federal Budget</li> </ul>	\$92,519	Australian Government Department of Health and Aged Cared
<b>Medicine Line Service</b>	To improve consumer knowledge of quality use of medicines and other health technologies and promote medication safety.	<ul style="list-style-type: none"> <li>Provision of a communications service to increase awareness of QUM principles and practices for consumers.</li> <li>To encourage consumer reporting of Adverse Drug Reactions with consumer call transfer to the AME Line, when indicated.</li> </ul>	\$218,200	Australian Government Department of Health and Aged Cared
<b>Adverse Medicine Event Line</b>	<p>To provide consumers with an avenue for reporting and discussing adverse experiences with medicines and provide independent, accurate and evidence-based information and improve health outcomes for consumers.</p> <p>Reporting of consumer-mediated Adverse Drug Reaction reports to the TGA to support national pharmacovigilance initiatives.</p> <p>To improve consumer knowledge of quality use of medicines and other health technologies and promote medication safety.</p>	<ul style="list-style-type: none"> <li>To increase consumer knowledge around safe and appropriate use of medicines.</li> <li>To assist the TGA with reporting of consumer mediated Adverse Drug Reactions.</li> <li>Provision of a communications and reporting service to increase awareness of QUM principles and practices for consumers.</li> </ul>	\$118,121	Australian Government Department of Health and Aged Cared
<b>COVID-19 Vaccine Support Program</b>	<p>To provide national access for consumers to report suspected Adverse Events Following Immunisation (AEFI) to the COVID-19 vaccines.</p> <p>To provide a national channel for consumers to seek medicines information about the safety of the COVID-19 vaccine for themselves or those they care for, to contribute to improved consumer knowledge of Quality Use of Medicines (QUM) health technologies and medicine safety.</p>	<ul style="list-style-type: none"> <li>Support national pharmacovigilance efforts for the COVID-19 vaccination program through timely and accurate reporting of consumer-initiated AEFI reports to the Therapeutic Goods Administration (TGA) from the NPS MedicineWise Adverse Medicine Events Line</li> <li>Provide both telephone-based and online mechanisms such as 'Ask a Pharmacist' via Facebook for consumers to access resources and services which provide evidence-based information about the COVID-19 vaccine.</li> </ul>	\$346,155	Australian Government Department of Health and Aged Cared